Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma

Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination with bendamustine and Rituxan (rituximab) (BR) as a treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in who have received at least two prior therapies.

The drug regimen was approved after being granted Accelerated Approval from the FDA. The US regulator’s decision was taken based on data derived from 80 patients ineligible for haematopoietic stem cell transplant.

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.